Episign

What Episign does

EpiSign Inc. is a Canadian biotech company founded in 2022 through a collaboration between Dr. Bekim Sadikovic and London Health Sciences Centre, headquartered in London, Ontario. The company develops the first clinically validated epigenomic diagnostic software for rare genetic conditions, using DNA methylation analysis (episignatures) read from peripheral blood samples via microarray technology. Its products include the EpiSign v6 classifier (covering 310+ episignature conditions, launched June 2026) and the EpiSign METRIC cloud-based software platform (launched October 2025), both powered by the proprietary EpiSign Knowledge Database, described as the world's largest epigenetic reference set for rare diseases. Sub-products include EpiSign Complete (comprehensive clinical assay, 250+ conditions), EpiSign Target (targeted review for resolving variants of uncertain clinical significance), and EpiSign Single (single-gene methylation testing).

EpiSign generates revenue through three streams: per-sample diagnostic testing fees through a global Clinical Testing Network of partner laboratories, cloud-based METRIC platform licensing to clinical labs and hospital systems (with APIs for integration into LIS/LIMS and hardware ecosystems), and research partnerships with academic institutions and pharmaceutical companies for episignature discovery and validation. Customers include molecular diagnostics programs, clinical genetics centers, rare disease research labs, and biopharma companies seeking validated biomarkers for stratification and companion diagnostics. Go-to-market combines enterprise field sales with channel partners across North America, the UK, Europe, the Middle East, and Australia, supported by peer-reviewed publications and conference-driven community adoption.

Operationally, the company runs lean (1-10 employees) and remains pre-commercial in scale despite a decade-plus research base and rapid 2025-2026 product launches. The firm is led by CEO Dan Sinai (joined August 2023 from IBM Canadian R&D) and Founder/CSO Dr. Bekim Sadikovic, with Kate Evans (Business Operations), Tom Currie (Finance), and Rob Denroche (Bioinformatics) on the executive team. To date, disclosed external funding is limited to public and quasi-public grants, including a CAD $640,000 award from the Ontario Brain Institute in March 2026 and Ontario Genomics support for the Synthetic Reference Epigenomics secure cloud framework project.

Name

Episign

Legal name

Episign Inc.

Website

https://episign.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

EpiSign Inc. is a Canadian biotech that develops clinically validated epigenomic diagnostic software using DNA methylation analysis and proprietary AI/ML classifiers to diagnose rare genetic diseases, serving clinical laboratories, hospitals, and research institutions across more than 25 countries via its METRIC cloud platform.

Ownership category

akta.pro rank

Product category

Epigenomic Diagnostic Software

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734), Services-Prepackaged Software (7372)

akta.pro primary industry

Epigenomics & Chromatin Profiling Services (HLAGANAF)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

Keywords

• Epigenomic diagnostics
• Rare disease testing
• DNA methylation analysis
• Clinical diagnostic software
• Episignature analysis

Headquarters

HQ city

London

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Diagnostic Testing Services: EpiSign provides epigenomic diagnostic testing through its clinical testing network. Healthcare providers submit patient samples for DNA methylation analysis, receiving actionable clinical reports. Revenue generated from test processing fees through partner laboratories.
2. METRIC Platform Licensing: Cloud-based software platform licensing to clinical laboratories, hospital systems, and research institutions. Partners integrate METRIC into their workflows to independently process, analyze, and interpret EpiSign data. Subscription or usage-based licensing model.
3. Research Partnerships: Collaborations with research institutions and pharmaceutical companies for episignature discovery and validation. May include research service fees, co-development arrangements, and potential milestone payments.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

EpiSign develops and sells the EpiSign METRIC cloud-based software platform, which interprets patient DNA methylation patterns (episignatures) to diagnose rare genetic disorders. The company markets clinical assay products (EpiSign Complete for comprehensive screening, EpiSign Target for variant-of-uncertain-significance resolution, and EpiSign Single for single-gene testing) and licenses its analysis platform through a global Clinical Testing Network of partner laboratories in 25+ countries.

Product overview

EpiSign Inc. offers EpiSign™ METRIC as its core cloud-based software platform for epigenomic diagnostics. The platform integrates with specialized assay products including EpiSign™ Complete (comprehensive clinical assay for 250+ episignature conditions) and EpiSign™ Target (targeted VUS resolution). All diagnostic capabilities are powered by the proprietary EpiSign™ Knowledge Database—the world's largest rare disease epigenetic reference—and driven by the v6 classifier covering 310+ episignature conditions. The system uses machine learning algorithms to analyze genome-wide DNA methylation patterns from peripheral blood samples, delivering reproducible, standardized interpretation across global laboratory partners.

Differentiator

Problem solved

Functional benefit

Brands

• EpiSign™ METRIC: Cloud-based software platform for interpreting epigenomic data for clinical diagnostics, screening for 200 episignature disorders.
• EpiSign™ Complete
• EpiSign™ Target
• EpiSign™ Single

Products and services

• EpiSign METRIC Cloud-based epigenomic diagnostic software platform that interprets DNA methylation data for clinical diagnostics. Powered by AI algorithms trained on the world's largest epigenetic database, METRIC enables laboratories to independently analyze and interpret patient episignature testing data with standardized, scalable analysis.
• EpiSign Complete First clinical assay validated to detect unique epigenetic signatures and methylation abnormalities for more than 250 episignature conditions. Used as a comprehensive screening test for individuals with suspected rare diseases.
• EpiSign Target Targeted review of methylation data intended to resolve variants of uncertain clinical significance (VUS) in genes with known epigenetic signatures. Achieves 32.4% diagnostic yield in cases unresolved by traditional genetic testing.
• EpiSign v6 Classifier DNA methylation episignature classifier expanding coverage to over 310 episignature conditions. Features improved sensitivity for subtle and mixed signals, better detection of partial or mosaic effects, and refined quantitative scoring approaches. Fully integrated with the EpiSign METRIC platform.
• EpiSign Knowledge Database World's largest epigenetic database for rare diseases containing thousands of reference samples and a growing list of genetic conditions. Powers the EpiSign classifier by providing validated episignature biomarkers for rare disease diagnostics.

Quantifiable outcome

• 18.7% diagnostic yield for comprehensive testing (EpiSign Complete)
• +4 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

16 partnerships are on record, tiered core, major and foundational.

• Ontario Brain Institute (OBI)coreStrategic or Co-development Partner · 19 March 2026OBI invested $640,000 through its Centre for Analytics to advance AI and brain health innovation. EpiSign is refining and validating the METRIC algorithm using OBI's advanced cloud computing platform and analytics expertise. Collaboration leverages federated learning and secure data analytics for rare disease diagnostics.
• Ontario Brain Institute (OBI)coreStrategic or Co-development Partner · 25 March 2025Joint initiative to improve diagnosis and care for people with rare neurological genetic disorders. OBI's Centre for Analytics provides AI application deployment expertise and cloud computing platform. Global launch planned for Q3 2025.
• Ontario GenomicsmajorStrategic or Co-development PartnerOntario Genomics funded initiative 'Synthetic Reference Epigenomics: Building a Secure Cloud Framework for Scalable Rare Disease Diagnostics.' Project focuses on developing privacy-preserving infrastructure for large-scale epigenomic data analysis and collaboration.
• IlluminacoreStrategic or Co-development PartnerInternational clinical trial partnership for validation of integrated genomic and epigenomic hardware and automated end-user EpiSign software. Involves institutions across 15 countries for large-scale patient testing.
• London Health Sciences Centre (LHSC)foundationalStrategic or Co-development PartnerFounding partner and site of Dr. Sadikovic's research laboratory. Collaboration between LHSC and Dr. Bekim Sadikovic led to EpiSign's founding in 2022. Home of the Verspeeten Clinical Genome Centre.
• Western UniversitymajorStrategic or Co-development PartnerDr. Sadikovic holds professorship positions in Pathology and Laboratory Medicine and Pediatrics departments. University affiliation enables ongoing research collaboration and talent development.
• Amsterdam UMC (Netherlands)majorChannel Partner/ Reseller/ DistributorClinical laboratory partner for EpiSign testing services in the Netherlands. Represented by Clinical Laboratory Geneticist Mariëlle Alders who provided endorsement for METRIC platform.
• Greenwood Genetic Centre (USA)majorChannel Partner/ Reseller/ DistributorPartner laboratory providing EpiSign genetic testing services in the United States. Staff Scientist Matt Tedder provided commentary on METRIC platform capabilities.
• NHS Manchester University (UK)majorChannel Partner/ Reseller/ DistributorNHS partner laboratory offering Whole Genome Methylation Profiling for rare diseases through the North West Genomic Laboratory Hub.
• PathWest (Western Australia)majorChannel Partner/ Reseller/ DistributorGovernment pathology service partner providing EpiSign testing services in Western Australia.
• MGZ Medical Genetics Centre (Germany)majorChannel Partner/ Reseller/ DistributorPartner laboratory offering EpiSign Beyond Exome epigenetic signature testing as part of their genetic diagnostics services.
• Cincinnati ChildrenmajorChannel Partner/ Reseller/ DistributorMajor children's hospital partner providing genetics and genomics diagnostic laboratory services including EpiSign testing.
• Sheba Global (Israel)majorChannel Partner/ Reseller/ DistributorInternational partner for patient services and EpiSign diagnostics, one of Israel's leading medical centers.
• NSW Health Genomics (Australia)majorChannel Partner/ Reseller/ DistributorGovernment health genomics service in New South Wales, Australia, providing statewide genomics diagnostic services.
• CHU de Reims (France)majorChannel Partner/ Reseller/ DistributorUniversity hospital partner for rare disease diagnostics and EpiSign testing services in France.
• External Scientific Advisory Board MembersmajorStrategic or Co-development PartnerDistinguished international experts including Dr. Gunnar Houge (Norway), Dr. Marco Tartaglia (Italy), Prof. David Genevieve (France), Dr. Jill Fahrner (Johns Hopkins), and Prof. Kym Boycott (Canada) providing scientific guidance and strategic oversight.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

• LinkedInca.linkedin.com/company/episign-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Episign